Compare Adaptive Biotechnologies Corp (ADPT) vs Sunrun Inc (RUN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Sunrun Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.09 (market cap $3.33B), while Sunrun Inc trades at $11.57 (market cap $2.91B). The key difference: Adaptive Biotechnologies Corp and Sunrun Inc are close in size by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Sunrun Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | RUN | |
|---|---|---|
Market Cap | $3.33B | $2.91B |
Sector | Health | Technology |
52-Week High | $22.37 | $21.41 |
52-Week Low | $10.24 | $9.07 |
Enterprise Value | $3.19B | $17.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Sunrun (RUN) trades at $12.97, up 1.81% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamental metrics with a low P/E of 6.09 and robust profitability margins, while recent news highlights the company's strategic partnership with Tesla for virtual power plants targeting AI data center demand. Cash flow trends show significant investing activity with positive net cash flow.
The outlook remains cautiously optimistic with analyst consensus at Buy (62%) and a $17.58 price target, though technical weakness and negative operating cash flow present near-term risks. The Tesla partnership offers growth potential in energy infrastructure, but execution risks and market volatility require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →
